Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Anal Cancer

Anal Cancer

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Anal Cancer

35 trials tracked for Anal Cancer: 5 in phase 3 or 4 and 4 with published results. The most-cited published study has 478 citations.

35Trials tracked
5Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 3 5 Phase 2 18 Phase 1 1 Other / NA 11
  1. Phase 3 Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions Completed · 478 cited
  2. Phase 3 Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia Completed · 56 cited
  3. Phase 3 Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). Completed · 27 cited
  4. Phase 3 Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064) Completed · 9 cited
  5. Phase 3 Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) Completed
  6. Phase 2 Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus Completed
Show 29 more trials
  1. Phase 2 Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer Completed
  2. Phase 2 A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal Completed
  3. Phase 2 A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) Completed
  4. Phase 2 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers Completed
  5. Phase 2 M7824 in Subjects With HPV Associated Malignancies Completed
  6. Phase 2 T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed
  7. Phase 2 Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer Completed
  8. Phase 2 Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer Completed
  9. Phase 2 Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream Completed
  10. Phase 2 Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed
  11. Phase 2 Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial Completed
  12. Phase 2 Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males Completed
  13. Phase 2 VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2 Completed
  14. Phase 2 Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer Completed
  15. Phase 2 [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers Completed
  16. Phase 2 Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer Completed
  17. Phase 2 Pembrolizumab in Metastatic Anal Cancer Completed
  18. Phase 1 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Completed
  19. N/A Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV Completed
  20. N/A A Message Framing Intervention for Increasing Parental Acceptance of Human Papillomavirus Vaccination Completed
  21. N/A The Prevent Anal Cancer Palpation Study Completed
  22. N/A Men's Beliefs About Associations Between HPV, Cancers, and HPV Vaccination Completed
  23. N/A Programs To Support You During Chemotherapy Completed
  24. N/A A Chatbot Intervention for Reducing HPV Vaccine Hesitancy Completed
  25. N/A The Self-Sampling Pilot Study Completed
  26. N/A Cancer in Patients With Gabapentin (GPRD) Completed
  27. N/A Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC Completed
  28. N/A Open Pilot Trial of a Mind-Body Sexual Well-Being Intervention for Female GI Cancer Survivors Completed
  29. N/A The Prevent Anal Cancer Self-Swab Study Completed

Showing the 35 most-cited and recently-updated of 35 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Anal Cancer: what the trials found

In the management of anal cancer and related conditions, carboplatin has demonstrated a statistically significant improvement in progression-free survival (PFS) compared to alternative treatments (9.3 vs. 7.4; p=0.0006) 5. Clinical observation was also utilized to monitor high-grade anal intraepithelial neoplasia at one year 4.

Immunological and prophylactic interventions show significant results in HPV management. V503 significantly reduced the combined incidence of HPV 6/11/16/18-related anogenital persistent infection (0.2 vs. 2.2; p=<0.001) 6. The 9vHPV vaccine demonstrated significant differences in geometric mean titers (GMTs) across various HPV types (p=<0.001) 7.

Treatment with imiquimod resulted in a reduction in physical symptom scores from baseline to four weeks post-randomization (-2.22 vs. -0.08) 3. Regarding cetuximab, trials showed no statistically significant difference in local failure rates at three years (0.259 vs. 0.353; p=0.218) 19, while another study reported locoregional failure rates of 42 and 20 respectively with a recorded QoL EORTC Global Score of 78.9 at one year 20.

Fludarabine was evaluated in clinical settings [17, 18].

Recent results — preliminary, needs further review

  • Acupuncture therapy was evaluated for chemotherapy-induced peripheral neuropathy (CIPN); results showed a mean change in severity of 5.9 and a reduction in the number of participants with Grade 2 or higher CIPN to 3 1.
  • Non-interventional data is available for a larger cohort of 460 patients 2.

For the clinician treating this condition

  • Carboplatin is associated with statistically significant improvements in progression-free survival (PFS) 5.
  • V503 and the 9vHPV vaccine are established interventions for managing HPV-related infections and titers, respectively [6, 7].
  • Imiquimod has been shown to reduce physical symptom scores in patients 3.

AI synthesis of 9 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.